Doctor Evidence Partnering with Healthcare Decision-Makers on Hepatitis C Evidence
PRWeb - Sun Aug 03, 5:30AM CDT
Doctor Evidence ("DRE"
TAL Education, Team Health Join The IBD 50 Resistance
at Investor's Business Daily - Fri Aug 01, 6:08PM CDT
Leading stocks took their licks in the past week, with only a small clique of IBD 50 stocks posting weekly gains. Among those, China-based TAL Education (XRS) hauled in an 11% gain to end the week at a new high. That left the chain of tutoring...
Final Glance: Biotechnology companies
AP - Fri Aug 01, 5:03PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
Midday Glance: Biotechnology companies
AP - Fri Aug 01, 12:35PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are down at 1 p.m.:
Pharmacyclics Q2 Earnings Get Mixed Reception
at Investor's Business Daily - Fri Aug 01, 11:35AM CDT
Biotech Pharmacyclics (PCYC) was seesawing on the stock market today after its Q2 sales beat consensus late Thursday, but the company declined to update its guidance. Pharmacyclics' sales more than doubled over the year-earlier quarter to $113...
Early Glance: Biotechnology companies
AP - Fri Aug 01, 10:08AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Shares of GILD Up 27.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Aug 01, 9:45AM CDT
SmarTrend identified an Uptrend for Gilead Sciences (NASDAQ:GILD) on April 22nd, 2014 at $72.56. In approximately 3 months, Gilead Sciences has returned 27.17% as of today's recent price of $92.27.
Oregon Medicaid targets expensive hepatitis drug
By JONATHAN J. COOPER - AP - Thu Jul 31, 9:09PM CDT
WILSONVILLE, Ore. (AP) — An Oregon Medicaid committee on Thursday significantly scaled back access to an effective — but expensive — new drug used to treat hepatitis C.
Stock Market News for July 31, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 31, 9:10AM CDT
Benchmarks ended Wednesday’s choppy trading session little changed after the Federal Reserve offered a mixed view on the economy
Biotech Earnings Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - ZACKS - Thu Jul 31, 9:01AM CDT
Following solid results from Amgen, among others, these biotech ETFs could be ones to watch.
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis
PR Newswire - Thu Jul 31, 8:20AM CDT
Today, Analysts Review released its research reports regarding AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Horizon Pharma Inc. (NASDAQ: HZNP), Gilead Sciences Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV) and Exelixis Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5305-100free.
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences
PR Newswire - Thu Jul 31, 7:40AM CDT
On Wednesday, July 30, 2014, the NASDAQ Composite ended at 4,462.90, up 0.45%, the Dow Jones Industrial Average finished the day 0.19% lower at 16,880.36, and the S&P 500 closed at 1,970.07, up 0.01%. During the session five out of ten sectors ended in positive. The S&P 500 Health Care Sector Index ended the day at 718.94, up 0.36%, and the index has advanced 2.05% in the last one month. Investor-Edge has initiated coverage on the following equities: IsoRay Inc. (NYSE MKT: ISR), Neurocrine Biosciences Inc. (NASDAQ: NBIX), OPKO Health Inc. (NYSE: OPK), Orexigen Therapeutics Inc. (NASDAQ: OREX), and Gilead Sciences Inc. (NASDAQ: GILD). Free research on these five companies can be accessed at:
Biotech Valuations Are Low Not Stretched. Here's Why.
at The Street - Thu Jul 31, 7:35AM CDT
If biotech companies can assuage concerns about long-term growth, multiples might expand.
Can the Earnings Rebound be Sustained? - Earnings Outlook
Sheraz Mian - Zacks Investment Research - Thu Jul 31, 2:34AM CDT
Can the Earnings Rebound be Sustained? - Earnings Outlook
Can the Earnings Rebound be Sustained? - Earnings Trends
Sheraz Mian - Zacks Investment Research - Thu Jul 31, 2:34AM CDT
Can the Earnings Rebound be Sustained? - Earnings Trends